Initial Treatment of Idiopathic Nephrotic Syndrome in Children with Mycophenolate Mofetil vs. Prednisone: A Prospective, Randomized, Controlled, Multicenter, Open, Phase 3, Noninferiority Study

被引:0
|
作者
Benz, Marcus R. [1 ,2 ]
Ehren, Rasmus [1 ]
Hoecker, Britta [3 ]
Fichtner, Alexander [3 ]
Querfeld, Uwe [4 ]
Hoyer, Peter F. [5 ]
Kemper, Markus J. [6 ]
Haffner, Dieter [7 ]
Dotsch, Joerg [1 ]
Konrad, Martin [8 ]
Sander, Anja Christine [9 ]
Meis, Jan [9 ]
Toenshoff, Burkhard [3 ]
Weber, Lutz Thorsten [1 ]
机构
[1] Univ Hosp Cologne, Cologne, Germany
[2] Pediat Nephrol Dachau, Dachau, Germany
[3] Univ Childrens Hosp Heidelberg, Heidelberg, Germany
[4] Charite Univ Med Berlin, Berlin, Germany
[5] Univ Duisburg Essen, Duisburg, Nordrhein Westf, Germany
[6] Asklepios Kliniken GmbH & Co KGaA, Hamburg, Germany
[7] Med Hsch Hannover Zentrum Kinderheilkunde & Jugen, Hannover, Niedersachsen, Germany
[8] Univ Munster, Munster, Nordrhein Westf, Germany
[9] Heidelberg Univ, Heidelberg, Baden Wurttembe, Germany
来源
关键词
D O I
10.1681/ASN.2024dxr49rap
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
SA-OR74
引用
收藏
页数:2
相关论文
共 50 条
  • [31] FOLFIRI versus irinotecan monodrug as second-line treatment in metastatic colorectal cancer patients: An open, multicenter, prospective, randomized controlled phase III clinical study.
    Guo, Weijian
    Zhang, Xiaowei
    Wang, Yusheng
    Zhang, Wen
    Liu, Xin
    Shen, Wei
    He, Yifu
    Zhu, Xiaodong
    Chen, Zhiyu
    Wang, Hong Qiang
    Huang, Mingzhu
    Zhang, Zhe
    Zhao, Xiaoying
    Qiu, Lixin
    Wang, Chenchen
    Sheng, Xuedan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study)
    Remy, Philippe
    Audard, Vincent
    Natella, Pierre Andre
    Pelle, Gaelle
    Dussol, Bertrand
    Leray-Moragues, Helene
    Vigneau, Cecile
    Bouachi, Khedidja
    Dantal, Jacques
    Vrigneaud, Laurence
    Karras, Alexandre
    Pourcine, Frank
    Gatault, Philippe
    Grimbert, Philippe
    Sahlia, Nawelle Ait
    Moktefi, Anissa
    Daugas, Eric
    Rigothier, Claire
    Bastuji-Garin, Sylvie
    Sahali, Dil
    KIDNEY INTERNATIONAL, 2018, 94 (06) : 1217 - 1226
  • [33] Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus
    Hess, Georg
    Rule, Simon
    Jurczak, Wojciech
    Jerkeman, Mats
    Santucci, Rodrigo
    Rusconi, Chiara
    Caballero, Dolores
    Joao, Cristina M.
    Witzens-Harig, Mathias
    Bence-Bruckler, Isabelle
    Cho, Seok-Goo
    Bandyopadhyay, Nibedita
    Goldberg, Jenna
    Bothos, John
    Enny, Christopher
    Vermeulen, Jessica
    Traina, Shana
    Dreyling, Martin H.
    BLOOD, 2015, 126 (23)
  • [34] Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor ibrutinib in combination with obinutuzumab vs. chlorambucil in combination with obinutuzumab in patients with treatment-naive CLL/SLL (PCYC-1130): iLLUMINATE.
    Flinn, Ian
    Moreno, Carol
    Gill, Devinder Singh
    Kipps, Thomas J.
    Shaw, Yun
    Li, Yunfeng
    Styles, Lori Appel
    James, Danelle Frances
    Gribben, John G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Adjuvant Radiotherapy after breast conserving Surgery for Breast cancer: Hypofractionation with simultaneous integrated Boost vs. Standard Fractionation: a proposed multicenter randomized controlled Phase III Treatment optimization study (HYPOSIB)
    Dellas, K.
    Krockenberger, K.
    Vonthein, R.
    Koenig, I
    Ziegler, A.
    Dunst, J.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 : 34 - 35
  • [36] A Multi-Center, Randomized, Double Blind, Phase III Clinical Trial Comparing Steroids/Placebo Vs. Steroids/Mycophenolate Mofetil As Initial Therapy for Acute Graft-Versus-Host Disease. Blood and Marrow Transplant Clinical Trials Network Study 0802
    Bolanos-Meade, Javier
    Logan, Brent R.
    Alousi, Amin M.
    Antin, Joseph H.
    Barowski, Kate
    Carter, Shelly L.
    Hexner, Elizabeth O.
    Horowitz, Mary M.
    Levine, John E.
    MacMillan, Margaret L.
    Martin, Paul J.
    Nakamura, Ryotaro
    Pasquini, Marcelo C.
    Weisdorf, Daniel J.
    Westervelt, Peter
    Ho, Vincent T.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S137 - S137
  • [37] A multicenter, randomized, placebo -controlled, double-blind phase 3 trial with open -arm comparison indicates safety and ef fi cacy of nephroprotective therapy with ramipril in children with Alport ? s syndrome see commentary
    Gross, Oliver
    Toenshoff, Burkhard
    Weber, Lutz T.
    Pape, Lars
    Latta, Kay
    Fehrenbach, Henry
    Lange-Sperandio, Baerbel
    Zappel, Hildegard
    Hoyer, Peter
    Staude, Hagen
    Koenig, Sabine
    John, Ulrike
    Gellermann, Jutta
    Hoppe, Bernd
    Galiano, Matthias
    Hoecker, Britta
    Ehren, Rasmus
    Lerch, Christian
    Kashtan, Clifford E.
    Harden, Markus
    Boeckhaus, Jan
    Friede, Tim
    KIDNEY INTERNATIONAL, 2020, 97 (06) : 1275 - 1286
  • [38] RESULTS OF THE GLOBE STUDY: A PHASE 3, RANDOMIZED, CONTROLLED, DOUBLE-ARM, OPEN-LABEL, MULTI-CENTER STUDY OF VB-111 COMBINED WITH BEVACIZUMAB VS. BEVACIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Cloughesy, Timothy
    Brenner, Andrew J.
    Butowski, Nicholas
    Cohen, Yael C.
    Lowenton-Spier, Noa
    Wen, Patrick
    NEURO-ONCOLOGY, 2018, 20 : 4 - 5
  • [39] mFOLFOXIRI plus Bev vs. mFOLFOX6+Bev for RAS mutant unresectable colorectal liver-limited metastases: A study protocol of a multicenter randomized controlled phase 3 (BECOME2) trial
    Tang, Wentao
    Wei, Ye
    Ren, Li
    Ye, Qing-Hai
    Liu, Tianshu
    Xu, Jianmin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [40] A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB VS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: STUDY 309/KEYNOTE-775
    Makker, V.
    Colombo, N.
    Herraez, A. Casado
    Santin, A.
    Colomba, E.
    Miller, D.
    Fujiwara, K.
    Pignata, S.
    Baron-Hay, S.
    Ray-Coquard, I.
    Shapira, R.
    Ushijima, K.
    Sakata, J.
    Yonemori, K.
    Kim, Y. M.
    Guerra, E. M.
    Sanli, U. A.
    Mccormack, M.
    Huang, J.
    Smith, A. D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A4 - A5